Skip to main content

Table 4 Change in IOP (mmHg) from baseline at weeks 1 to 3 (worse eye, ANCOVA, PP population)

From: A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension

  Latanoprost concentration (μg/mL)
  50 75 100 125
Week 1
8 a.m. IOP
 N 69 66 71 68
 LS mean change (mmHg)* −9.11 −8.38 −8.85 −8.40
 Adjusted difference in LS mean ± SEM   0.73 ± 0.50 0.25 ± 0.50 0.71 ± 0.50
 (90% CI)   (−0.10, 1.57) (−0.57, 1.07) (−0.11, 1.54)
 p-value   0.926 0.696 0.922
4 p.m. IOP
 N 69 66 71 68
 LS mean change (mmHg)* −8.07 −7.63 −8.04 −7.46
 Adjusted difference in LS mean ± SEM   0.44 ± 0.48 0.03 ± 0.47 0.61 ± 0.47
 (90% CI)   (−0.35, 1.22) (−0.74, 0.79) (−0.17, 1.38)
 p-value   0.820 0.522 0.902
Week 2
8 a.m. IOP
 N 69 66 71 68
 LS mean change (mmHg)* −9.29 −9.56 −9.31 −9.05
 Adjusted difference in LS mean ± SEM   −0.27 ± 0.44 −0.02 ± 0.43 0.24 ± 0.44
 (90% CI)   (−1.00, 0.46) (−0.73, 0.70) (−0.49, 0.96)
 p-value   0.269 0.485 0.705
4 p.m. IOP
 N 69 66 71 67
 LS mean change (mmHg)* −8.28 −8.19 −8.21 −7.65
 Adjusted difference in LS mean ± SEM   0.08 ± 0.41 0.07 ± 0.40 0.63 ± 0.41
 (90% CI)   (−0.60, 0.76) (−0.60, 0.73) (−0.04, 1.30)
 p-value   0.578 0.565 0.939
Week 3
8 a.m. IOP
 N 68 65 71 66
 LS mean change (mmHg)* −9.68 −9.72 −9.79 −9.15
 Adjusted difference in LS mean ± SEM   −0.04 ± 0.46 −0.12 ± 0.45 0.53 ± 0.45
 (90% CI)   (−0.79, 0.71) (−0.85, 0.62) (−0.22, 1.28)
 p-value   0.463 0.396 0.879
4 p.m. IOP
 N 68 64 71 66
 LS mean change (mmHg)* −8.61 −8.60 −8.65 −8.06
 Adjusted difference in LS mean ± SEM   0.01 ± 0.45 −0.04 ± 0.44 −0.55 ± 0.45
 (90% CI)   (−0.73, 0.76) (−0.78, 0.68) (−0.18, 1.29)
 p-value   0.512 0.464 0.892
  1. ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
  2. *Adjusting for baseline IOP (covariate) with dose group and center as factors.
  3. Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
  4. One-sided p-value.